IP Library Granted Patent US 8,012,964
Granted Patent B2
US 8,012,964 · App. 10/593,691 · Granted Sep 6, 2011

9-substituted 8-oxoadenine compound

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,964
App. No.
10/593,691
Granted
Sep 6, 2011
Kind
B2
Abstract

The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z 1 represents alkylene, X 2 represents oxygen atom, sulfur atom, SO 2 , NR 5 , CO, CONR 5 , NR 5 CO and the like, Y 1 , Y 2 and Y 3 represent independently a single bond or an alkylene group, X 1 represents oxygen atom, sulfur atom, NR 4 (R 4 is hydrogen atom or an alkyl group) or a single bond, R 2 represents a substituted or unsubstituted alkyl group, R 1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.

Claims (4)

1. Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound or its pharmaceutically acceptable salt of claim 1 as an active ingredient and a carrier.

3. Methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate.

4. A pharmaceutically acceptable salt of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060138/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2020
From: ASTRAZENECA AKTIEBOLAG
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 051584/0893 →
CHANGE OF NAME Recorded Oct 17, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034014/0418 →
MERGER Recorded Jul 8, 2011
From: DAINIPPON PHARMACEUTICAL CO., LTD.; SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 026565/0837 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THIRD ASSIGNOR'S EXECUTION DATE PREVIOUSLY RECORDED ON REEL 018598, FRAME 0367. ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Recorded Jan 16, 2007
From: KURIMOTO, AYUMU; HASHIMOTO, KAZUKI; ISOBE, YOSHIAKI; BROUGH, STEPHEN; MILLICHIP, IAN; WADA, HIROKI; BONNERT, ROGER; MCINALLY, THOMAS
To: DAINIPPON SUMITOMO PHARMA CO., LTD.; ASTRAZENECA AKTIEBOLAG
Reel/Frame 018809/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2006
From: KURIMOTO, AYUMU; HASHIMOTO, KAZUKI; ISOBE, YOSHIAKI; BROUGH, STEPHEN; MILLICHIP, IAN; WADA, HIROKI; BONNERT, ROGER; MCINALLY, THOMAS
To: ASTRAZENECA AKTIEBOLAG; DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 018598/0367 →